Publications
Detailed Information
Safety and antitumor activity of pembrolizumab in patients with estrogen receptor–positive/human epidermal growth factor receptor 2–negative advanced breast cancer
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Rugo, Hope S. | - |
dc.contributor.author | Delord, Jean-Pierre | - |
dc.contributor.author | Im, Seock-Ah | - |
dc.contributor.author | Ott, Patrick A. | - |
dc.contributor.author | Piha-Paul, Sarina A. | - |
dc.contributor.author | Bedard, Philippe L. | - |
dc.contributor.author | Sachdev, Jasgit | - |
dc.contributor.author | Le Tourneau, Christophe | - |
dc.contributor.author | van Brummelen, Emilie M. J. | - |
dc.contributor.author | Varga, Andrea | - |
dc.contributor.author | Salgado, Roberto | - |
dc.contributor.author | Loi, Sherene | - |
dc.contributor.author | Saraf, Sanatan | - |
dc.contributor.author | Pietrangelo, Dina | - |
dc.contributor.author | Karantza, Vassiliki | - |
dc.contributor.author | Tan, Antoinette R. | - |
dc.date.accessioned | 2022-03-22T09:10:11Z | - |
dc.date.available | 2022-03-22T09:10:11Z | - |
dc.date.created | 2019-06-20 | - |
dc.date.created | 2019-06-20 | - |
dc.date.created | 2019-06-20 | - |
dc.date.created | 2019-06-20 | - |
dc.date.issued | 2018-06 | - |
dc.identifier.citation | Clinical Cancer Research, Vol.24 No.12, pp.2804-2811 | - |
dc.identifier.issn | 1078-0432 | - |
dc.identifier.other | 76256 | - |
dc.identifier.uri | https://hdl.handle.net/10371/177189 | - |
dc.description.abstract | Purpose: We investigated the safety and antitumor activity of the anti-programmed death 1 monoclonal antibody pembrolizumab in patients with estrogen receptor-positive (ER+)/human epidermal growth factor receptor 2-negative (HER2(-)) advanced breast cancer with programmed death ligand 1-positive (PD-L1-positive) tumors in the phase Ib open-label, multicohort KEYNOTE-028 (NCT02054806) study. Patients and Methods: Patients with ER+/HER2(-)advanced breast cancer with PD-L1-positive tumors (combined positive score >= 1) received pembrolizumab (10 mg/kg every 2 weeks) up to 2 years or until confirmed progression/intolerable toxicity. Primary endpoints were safety and overall response rate (ORR), based on Response Evaluation Criteria in Solid Tumors, version 1 (RECIST v1.1) as assessed by investigator review. Results: Between April 2014 and January 2015, 25 patients were enrolled. Median number of prior therapies for breast cancer, including endocrine agents, was 9 (range, 3-15). Median follow-up was 9.7 months (range, 0.7-31.8 months). Three patients experienced partial response (PR) and none experienced complete response (CR), resulting in an ORR of 12.0% (95% CI, 2.5%-31.2%); 16% of patients had stable disease (SD) and clinical benefit rate (CR + PR + [SD for >= 24 weeks]) was 20% (95% CI, 7-41). Median duration of response was 12.0 months (range, 7.4-15.9 months). The incidence of treatment-related adverse events was 64%; nausea (20%) and fatigue (12%) were most common and were predominantly grade 1/2. No treatment-related discontinuations or deaths occurred. Conclusions: Pembrolizumab was well tolerated with modest but durable overall response in certain patients with previously treated, advanced, PD-L1-positive, ER+/HER2(-) breast cancer. (C) 2018 AACR | - |
dc.language | 영어 | - |
dc.publisher | American Association for Cancer Research | - |
dc.title | Safety and antitumor activity of pembrolizumab in patients with estrogen receptor–positive/human epidermal growth factor receptor 2–negative advanced breast cancer | - |
dc.type | Article | - |
dc.contributor.AlternativeAuthor | 임석아 | - |
dc.identifier.doi | 10.1158/1078-0432.CCR-17-3452 | - |
dc.citation.journaltitle | Clinical Cancer Research | - |
dc.identifier.wosid | 000435462700011 | - |
dc.identifier.scopusid | 2-s2.0-85051820213 | - |
dc.citation.endpage | 2811 | - |
dc.citation.number | 12 | - |
dc.citation.startpage | 2804 | - |
dc.citation.volume | 24 | - |
dc.identifier.sci | 000435462700011 | - |
dc.description.isOpenAccess | Y | - |
dc.contributor.affiliatedAuthor | Im, Seock-Ah | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.subject.keywordPlus | 1ST-LINE THERAPY | - |
dc.subject.keywordPlus | OPEN-LABEL | - |
dc.subject.keywordPlus | PHASE-2 | - |
dc.subject.keywordPlus | PALBOCICLIB | - |
dc.subject.keywordPlus | IPILIMUMAB | - |
dc.subject.keywordPlus | EXPRESSION | - |
dc.subject.keywordPlus | MULTICENTER | - |
dc.subject.keywordPlus | MONOTHERAPY | - |
dc.subject.keywordPlus | LETROZOLE | - |
dc.subject.keywordPlus | EFFICACY | - |
- Appears in Collections:
- Files in This Item:
- There are no files associated with this item.
Item View & Download Count
Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.